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The impact of anti-diabetic drugs on
colorectal cancer risk in a large
cohort of women with diabetes
I
n order to investigate whether an association between
anti-diabetic drugs and the risk of colorectal cancer
exists in women with diabetes mellitus (DM) in
Taiwan, we designed a population-based cohort study
using data from Taiwan National Health Insurance
Database. There were 19,863 women aged 20 or older
with newly diagnosed DM (International Classification
of Diseases (ICD) 9th Revision, ICD-9 codes 250 and
A181) and currently using anti-diabetic drugs in 2000
2007 (mean age 54.5 years, standard deviation 12.9 years,
and age range 2093). The index date for each case was
defined as the date of diagnosis of colorectal cancer.
Subjects diagnosedwith cancer before the index date were
excluded from the study.
After adjusted for covariates, Cox proportional hazard
analysis showed that the hazard ratios (HR) of colorectal
cancer were 3.56 (95% CI2.026.72) in women with
ever-use of sulfonylureas and 0.42 (95% CI0.280.64)
in women with ever-use of metformin compared with the
non-use group (Table 1).
There is a growing body of evidence to show that
metformin is associated with a substantially decreased
risk of cancers (14). In Decensi et al.’s meta-analysis, a
31% reduction of overall cancer risk (95% CI0.610.79)
is found in patients using metformin compared with the
other anti-diabetic drugs (2). The present study also
showed women with ever-use of metformin could have a
58% reduced risk of colorectal cancer. Three studies in
Japan recently have also revealed the effect of metformin
on suppressing colonic epithelial proliferation in mice
and in humans, and further inhibiting colorectal carci-
nogenesis (57). The authors suggest that metformin may
play a promising role in the chemoprevention of color-
ectal cancer (57).
A retrospective cohort study by Currie et al. in UK (8)
revealed that sulfonylurea monotherapy could increase
1.8-fold risk of colorectal cancer (95% CI1.292.53). In
the present study, women with ever-use of sulfonylureas
increased 3.6-fold risk of colorectal cancer. Previous
studies have supported the hypothesis that hyperinsuli-
nemia may play a key role in colorectal carcinogenesis
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Table 1. Cox model hazard ratios (HR) and 95% conﬁdence intervals (CI) of colorectal cancer associated with anti-diabetic
drugs and covariates, 20002007
Variable Crude HR 95% CI Adjusted HR 95% CI
Age group (years)
2039 1.00  1.00 
4064 3.10 0.979.90 2.74 0.868.77
]65 6.24 1.9420.04 5.19 1.6116.71
Medications
Sulfonylureas (ever-use vs non-use) 2.47 1.454.20 3.56 2.026.72
Metformin (ever-use vs non-use) 0.63 0.430.93 0.42 0.280.64
Insulins (ever-use vs non-use) 0.75 0.381.48 
Thiazolidinediones (ever-use vs non-use) 0.88 0.541.48 
Alpha-glucosidase inhibitors (ever-use vs non-use) 0.92 0.561.51 
Aspirin (ever-use vs non-use) 1.05 0.701.57 
Other non-steroidal anti-inflammatory drugs (ever-use vs non-use) 1.25 0.463.40 
Statins (ever-use vs non-use) 1.21 0.831.76 
Co-morbidities
Obesity (yes vs no) 1.07 0.264.33 
Colorectal adenomas (yes vs no) 1.76 0.2512.61 
Inflammatory bowel diseases (yes vs no)*  
Alcoholism (yes vs no)*  
*No case was found
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Citation: Libyan J Med 2012, 7: 17532 - DOI: 10.3402/ljm.v7i0.17532(810). Because sulfonylureas can stimulate secretion of
insulin, it may partially explain why patients using
sulfonylureas are at an elevated risk of colorectal cancer.
Because the mechanism of anti-diabetic drugs on the
risk of colorectal cancer remains unproven, more pro-
spective intervention trials are required to definitively
address this issue.
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